Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function

Wong and colleagues show that human lymphocytes are highly susceptible to panobinostat, which alters their signaling pathways and is cytotoxic at a much lower dose than needed for antitumor activity. They caution against the combined use of panobinostat with immunotherapy for melanoma. Histone deacetylase inhibitors (HDACi) have been reported to increase tumor antigen expression, and have been successfully tested as adjuvants for melanoma immunotherapy in mouse models. In this work, we tested the effects of a pan-HDACi on human lymphocytes and melanoma cell lines. Effects of the pan-HDACi panobinostat (LBH589) on cell viability, cell cycle, apoptosis, and DNA damage were determined in peripheral blood mononuclear cells (PBMC) from 2 healthy donors, 13 patients with metastatic melanoma, 2 bone marrow samples from patients with different malignances, and 12 human melanoma cell lines. Intracellular signaling in lymphocytes, with or without cytokine stimulation, was analyzed by phospho-flow cytometry in one of each type. The IC50 in PBMCs was <20 nmol/L compared with >600 nmol/L in melanoma cell lines; >40% apoptotic cell death in PBMCs versus <10% in melanoma cell lines was seen at the same concentration. Phospho-histone variant H2A.X (pH2A.X) increased 2-fold in healthy donor PBMCs at 1 nmol/L, whereas the same effect in the melanoma cell line M229 required 10 nmol/L. pH2A.X was inhibited slightly in the PBMCs of 3 patients with metastatic melanoma at 1 nmol/L and in the melanoma cell line M370 at 10 nmol/L. Panobinostat inhibited phospho-STAT1/3/5/6, -p38, -ERK, -p53, -cyclin D3, and -histone H3 in flow cytometry–gated healthy donor B and T cells, whereas it induced up to 6-fold activation in patients with metastatic melanoma and bone marrow samples. In human lymphocytes, panobinostat alters key lymphocyte activation signaling pathways and is cytotoxic at concentrations much lower than those required for melanoma antitumor activity, resulting in an adverse therapeutic window. Cancer Immunol Res; 2(5); 459–68. ©2014 AACR.

[1]  P. Atadja,et al.  Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies , 2013, Leukemia.

[2]  J. Wolchok,et al.  Combining cancer immunotherapy and targeted therapy. , 2013, Current opinion in immunology.

[3]  L. Rhodes,et al.  Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat , 2012, Breast Cancer Research.

[4]  A. Ribas,et al.  Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines , 2012, Molecular Cancer.

[5]  E. Seto,et al.  Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer , 2012, Immunology and cell biology.

[6]  P. Mischel,et al.  Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway , 2011, PloS one.

[7]  S. Nelson,et al.  Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway , 2011, Journal of Translational Medicine.

[8]  R. Wilcox,et al.  Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management , 2011, American journal of hematology.

[9]  A. Bowcock,et al.  Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma , 2011, Clinical Cancer Research.

[10]  S. Bates,et al.  Histone deacetylase inhibitors: emerging mechanisms of resistance. , 2011, Molecular pharmaceutics.

[11]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[12]  R. Johnstone,et al.  Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies , 2011, Proceedings of the National Academy of Sciences.

[13]  Song Liu,et al.  Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. , 2011, Free radical biology & medicine.

[14]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[15]  B. Comin-Anduix,et al.  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.

[16]  K. Anderson,et al.  HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells , 2010, Leukemia.

[17]  R. Balderas,et al.  Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma , 2010, PloS one.

[18]  Paul S Mischel,et al.  Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 , 2010, Journal of Translational Medicine.

[19]  Wayne W. Hancock,et al.  Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells , 2009, Nature Reviews Drug Discovery.

[20]  F. Marincola,et al.  Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. , 2009, Cancer research.

[21]  P. Atadja.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[22]  G. Kao,et al.  The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer , 2009, Molecular Cancer Therapeutics.

[23]  R. Gopaul,et al.  Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. , 2008, Cancer research.

[24]  L. Poling,et al.  Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage , 2008, Pigment cell & melanoma research.

[25]  Y. Furukawa,et al.  Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. , 2008, The Journal of investigative dermatology.

[26]  T. Tomasi,et al.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.

[27]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[28]  W. Hancock,et al.  Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques. , 2008, Transplantation proceedings.

[29]  H. Verheul,et al.  Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[30]  S. Szabo,et al.  Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. , 2007, Blood.

[31]  Garry P Nolan,et al.  Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling , 2006, Nature Methods.

[32]  M. T. Pedersen,et al.  Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. , 2005, Cancer research.

[33]  Michael Bitzer,et al.  Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. , 2005, Cancer research.

[34]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[35]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Marks,et al.  Modulation of Renal Disease in MRL/lpr Mice by Suberoylanilide Hydroxamic Acid1 , 2004, The Journal of Immunology.

[37]  P. Hersey,et al.  The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. , 2004, Molecular cancer therapeutics.

[38]  P. Hersey,et al.  The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. , 2003, Biochemical pharmacology.

[39]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[40]  T. Tomasi,et al.  Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1 , 2000, The Journal of Immunology.

[41]  H. Saito,et al.  Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. , 2000, Blood.

[42]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[43]  A. Ribas,et al.  A Histone Deacetylase Inhibitor (HDACI) Sensitizes B16 Melanoma to Adoptive Transfer (AT) Immunotherapy , 2006 .

[44]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[45]  Lucia Altucci,et al.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.

[46]  L. Altucci,et al.  ERRATUM: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.